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for the period 2002–2005, for the 180 most selling substances
were used to calculate a chain price index. A regression model
was used to estimate the effects of analog substitution, i.e
switches from one substance to another of the same class, for 
5 major products whose patent expired during the period.
RESULTS: The general price level of pharmaceuticals has fallen
15% during the period and off-patent drugs have experienced a
40% fall in price level. In addition to the direct effect on prices
of a substance due to generic competition, there has also been
analog substitution effect from patented drugs to off-patent
drugs. For two groups of pharmaceuticals, statins and PPIs, there
were signiﬁcant substitution effects between substances due to
the changes in relative prices. CONCLUSIONS: Generic substi-
tution in Sweden has been effective in reducing prices of off-
patent pharmaceuticals. Generic substitution has also had more
farreaching effects than what has been previously believed. There
has been a move from patented to off-patent products within the
same therapeutic area.
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OBJECTIVE: Hungary’s accession to the European Union in
May 2004 compelled reconsideration of the social insurance
inclusion of pharmaceutical products. The Ofﬁce of Health Tech-
nology Assessment (HTA) of the National Institute for Strategic
Health Research was formed in 2004 with the aim of establish-
ing an independent institution to support decision-makers in
their rational use of health care resources. METHODS: The
Ofﬁce provides an organisational framework for the technology
assessment that forms the basis for the medicine subsidy
approval policy of the National Health Insurance Fund, and per-
forms the related medical and economic assessment duties. The
National Health Insurance Fund makes decisions regarding the
granting of subsidies for medicines, based on the ﬁndings pre-
sented by the Ofﬁce of HTA, which X determines the profes-
sional guidelines for analysing health technology, coordinates the
assessment of new and existing technologies, and issues instruc-
tions for the use of individual technologies X provides reliable
and undistorted information for the appraisal of individual pro-
cedures, comparing them with alternative opportunities for the
use of resources based on a combination of clinical evidence, efﬁ-
cacy and cost-effectiveness factors, X facilitates the appropriate
use of cost-effective health care technologies, and provides
support for decision-makers. RESULTS: The majority of appli-
cations were related to anti-tumour drugs and products designed
to treat diseases of the cardiovascular or central nervous system.
The Ofﬁce also performs problem-oriented comparative exami-
nations, such as the comprehensive policy study of Positron
Emission Tomography (PET) and Gamma-knife Surgery, Drug-
eluting Coronary Stents, etc. CONCLUSION: In the initial
period, staff at the Ofﬁce of Health Technology Assessment
focused primarily on assessments of medicines to determine their
eligibility for social insurance funding, but as the new institu-
tional structure becomes more ﬁrmly established, it is increas-
ingly able to perform thorough, comprehensive assessments of
other health technologies.
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OBJECTIVES: Anwendungsbeobachtungen (AWBs) are a
common type of postmarketing surveillance studies in Germany.
They provide information about medical beneﬁt, safety, and
effectiveness of drugs in daily practice and can support reim-
bursement decisions. As practice based research gains in impor-
tance the scientiﬁc quality of AWBs was evaluated. METHODS:
The German drug law demands the reporting of AWBs to
NASHIP. In the examined six-month period (July to December
2005), 453 AWBs were announced to NASHIP. Onehun-
dredeighteen were announced for the ﬁrst time, the others were
supplementary information to ongoing AWBs. AWB-conducting
companies were asked for more detailed information and AWBs
designs were analysed by a validated data entry form that was
based on recommendations of the Federal Institute for Drugs and
Medical Devices for the conduct of AWBs. RESULTS: One
hundred-eight AWBs included statements about goals: 46%
listed drug utilisation, 87% safety, 68% effectiveness and 24%
QoL. Only a third of AWBs chose a suitable design, basically
those that examined safety and drug-utilisation. Only 10% were
comparative. Most evaluated drugs were high-priced up to costs
of Euro 4500 per prescription. Almost 50% of all drugs had
obtained marketing authorisation during the last ﬁve years.
Median observation time per patient was 140 days. Only 19%
of all AWBs mentioned a planned publication of results explic-
itly. CONCLUSIONS: This study showed the very heterogeneous
quality of AWBs in Germany. In most AWBs the marketing aspect
dominated obviously and they were not suitable for reimburse-
ment decisions on the basis of the price-beneﬁt ratio.
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OBJECTIVES: The aim of the study was to determine the cost-
effectiveness ratio of professionals in ﬁve Spanish primary care
teams (Spanish “EAPs”) on the basis of Adjusted Clinical Groups
(ACGs). METHODS: Retrospective descriptive study. We
included all patients attended by ﬁve EAPs in 2004. Principal
measurements: age, sex, consultation episodes/reasons, total
cost/expense (semi-ﬁxed: personnel, procurement; variable:
pharmaceutical expense, referrals, tests), department, centre,
physician in charge (Spanish “UBA”—basic care unit) and a
qualitative synthetic index (Spanish “ISC”) drawn from 36
process and outcome indicators relating to health care practice.
Every patient was assigned to an exclusive ACG/category. We
produced the adjusted efﬁciency index (Spanish “IE”) indicating
relative efﬁciency with reference to a standard (observed/
expected; grouper-6.0; Johns Hopkins University) and the 
ISC for each centre and UBA. We analysed the correlation of IE
and ISC (Spearman’s rank correlation) and a range of indirect
standardisations to adjust the results. Statistical signiﬁcance 
p < 0.05. RESULTS: We studied 81,085 patients (use intensity
76.9%), with a mean of 5.0 ± 3.6 and 8.0 ± 8.2 visits per patient
per year. The total cost per attended patient per year was 
340 euros (reference average relative weight). Pharmaceutical
prescription costs accounted for more than 60%. The efﬁciency
indices (IE) of the centres were: 0.92, 0.94, 0.95, 1.06, and 1.06
(p = 0.000). The qualitative synthetic indices (ISC) were: 68.9%,
66.1%, 45.8%, 43.4%, and 31.6% (p = 0.000). An inverse cor-
relation was found between IE and ISC (p < 0.001; R2 = 36%).
The explanatory power of the classiﬁcation was 53%. CON-
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CLUSION: The association of cost-effectiveness dimensions may
provide us with an estimated measure of EAPs’ ability to resolve
issues, between centres and UBAs. In general, a direct associa-
tion holds between the efﬁciency index and higher effectiveness
of interventions. The data must be assessed cautiously with ref-
erence to the external validity of the study.
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OBJECTIVES: During recent years, due to the importance of
health services, health care managers attend to increase of hos-
pital services quality. The European Foundation for Quality
Management (EFQM) Excellence Model was performed as a
competition framework to recognition of achievement to orga-
nizational quality, performance excellence and growth of orga-
nizational knowledge about quality and performance excellence.
METHODS: The method of this research is descriptive and
cross-sectional. This research had been done in Alborz and
panzdah khordad varamin hospitals. Data gathering tool was the
EFQM questionnaire that had been completed during group
working sessions, interview with leaders of the hospitals and
referring to necessitous units. Research data had been gathered
according to nine criteria of in the hospitals. RESULTS: Find-
ings had been showed that Alborz hospital has had the higher
score in leadership criterion (46.1%), policy and strategy
(50.6%) processes (61%). Panzdah khordad hospital has had the
higher score in people (47.39%), partnership and resources
(49.5%), customer results (46.1%), people results (39%), society
results (40.6%) and key performance results (56.25%). Totally,
the ﬁnding shows that Panzdah khordad hospital had been
higher score 471.56 and then Alborz hospital with 439.55
scores. CONCLUSION: Assessment of hospital performance
based on The EFQM Model is the ﬁrst empirical experience in
Iranian hospitals. The ﬁndings have showed that European
Organizational Excellence Model is very applicable in health
care. Benchmark and supervision to hospital performance will
be possible by using the model especially in management atten-
tion and follow up to hospital. The assessment gave an overall
picture of the organization and was a ﬁrst step to introduce a
systemic view and a common view.
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OBJECTIVE: To compare the cost-effectiveness of etanercept +
methotrexate (MTX) and inﬂiximab + MTX for the treatment
of severe rheumatoid arthritis (SRA) patients in Brazil.
METHODS: An analytic-decision model for projecting the
annual costs of treating SRA in Brazil was developed consider-
ing local procedures and a payer perspective. The clinical effec-
tiveness was based on American College of Rheumatology
criteria for 20% (ACR20), 50% (ACR50), and 70% (ACR70).
For inﬂiximab a 70 kg patient was considered. The data used in
the analysis were obtained from public sources: Ofﬁcial Price
List; products labels; Ofﬁcial Physicians Fees List and local arti-
cles published in indexed journals. To ensure similarities in
patient proﬁle, the ACR20, 50, 70 responses from: Weinblatt,
1999 (etanercept) and Maini, 1999 (inﬂiximab) were chosen for
the effectiveness measures. RESULTS: For the annual treatment
cost, Inﬂiximab 10 mg/kg every 4 weeks (INF.10/4 = R$255,935)
was the most expensive therapy followed by inﬂiximab 10 mg/kg
every 8 weeks (INF.10/8 = R$148,284); etanercept 50 mg every
week (ETA = R$88,247); inﬂiximab 3 mg/kg every 4 weeks
(INF.3/4 = R$80,104); and inﬂiximab 3 mg/kg every 8 weeks
(INF.3/8 = R$47,809). However, assuming INF.3/4 as the average
dosing schedule, ETA shows lower average cost-effectiveness
(C/E) ratios for ACR20: (ETA) R$124,291 vs. (INF.3/4)
R$160,209; ACR50: (ETA) R$226,273 vs. (INF.3/4)
R$276,222; and ACR70: (ETA) R$588,310 vs. (INF.3/4)
R$728,222. Etanercept offers favorable C/E ratios in 3 out of 4
scenarios for each ACR response. This was conﬁrmed by a one-
way sensitivity analysis applying a 10% variance in either prices
or in ACR responses. The incremental cost-effectiveness ratio
ranged from R$38,772 to R$203,522 for ETA relative to
INF.3/4. CONCLUSIONS: Findings suggest etanercept as a com-
petitive cost-effectiveness therapy. Etanercept performs better
especially when it is compared with the intermediate/high
dosages per kilo of inﬂiximab.
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OBJECTIVE: To assess the cost-effectiveness of a single intra-
venous dose of zoledronic acid 5 mg (ZOL) compared to a daily
regimen of oral risedronate 30 mg (RIS) over 2 months in the
long-term (2-year) management of Paget’s disease of the bone
(PDB) in Germany. METHODS: A model-based incremental
cost-effectiveness analysis was conducted over four half-year
cycles. Clinical efﬁcacy was reﬂected in four health states:
response, non-response, relapse, no-relapse. Response was
deﬁned as normalization of the serum alkaline phosphatase
(SAP) value after 6 months. Relapse was deﬁned as an increase
in SAP of at least 50% from the value at 6 months and at least
1.25 times the upper normal limit. Retreatment was assumed in
case of non-response or relapse. Efﬁcacy data were obtained
from two 6-month randomized clinical trials which compared
ZOL with RIS in patients with PDB. Relapse data were obtained
from the extended observation phase of the trial, in which SAP
was measured at 6-monthly intervals to determine whether
patients were still in response. The analysis was conducted from
the German payers’ perspective. Only direct health care costs
such as those for physician visits, SAP measurement and drug
administration were considered. Cost data were derived from
published sources for the year 2006. Costs and effects in the
second year were discounted by 5%. A probabilistic sensitivity
analysis (PSA) was performed to investigate the robustness of the
results. RESULTS: Due to more responders and longer remis-
sion, treatment with ZOL resulted in an incremental of 6.2
months in response and a cost saving of 243 € over 2 years com-
pared to RIS. The results of the PSA indicated that ZOL was
more effective and cost-saving with 100% certainty. CONCLU-
SION: ZOL presents a dominant treatment option in the long-
term management of PDB indicating superior effectiveness at a
lower cost.
